FLX BIO INC has a total of 21 patent applications. It decreased the IP activity by 45.0%. Its first patent ever was published in 2017. It filed its patents most often in WIPO (World Intellectual Property Organization), United States and Taiwan. Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are AXOVANT SCIENCES GMBH, TARCIC NORA and BESINS ISCOVESCO LAB.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 5 | |
#2 | United States | 4 | |
#3 | Taiwan | 3 | |
#4 | China | 2 | |
#5 | Brazil | 1 | |
#6 | Canada | 1 | |
#7 | Israel | 1 | |
#8 | Republic of Korea | 1 | |
#9 | Mexico | 1 | |
#10 | Singapore | 1 | |
#11 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Heterocyclic compounds | |
#3 | Medical preparations |
# | Name | Total Patents |
---|---|---|
#1 | Younai Ashkaan | 13 |
#2 | Robles-Resendiz Omar | 12 |
#3 | Ketcham John Michael | 12 |
#4 | Zibinsky Mikhail | 12 |
#5 | Biannic Berenger | 12 |
#6 | Wustrow David Juergen | 12 |
#7 | Reilly Maureen Kay | 10 |
#8 | Hu Dennis X | 10 |
#9 | Powers Jay Patrick | 9 |
#10 | Walker James Ross | 9 |
Publication | Filing date | Title |
---|---|---|
US2019142834A1 | Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof | |
WO2018187509A1 | Heterocyclic compounds as chemokine receptor modulators | |
WO2018049271A1 | Chemokine receptor modulators and uses thereof | |
KR20190041471A | Chemokine receptor modulators and uses thereof |